Overcoming graft rejection is the main obstacle when it comes to stem cell regeneration or organ transplantation. Scientists are investigating whether Veto Cell technology, which selectively tunes immune response, can change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated. Itamar Shimat, Cell Source's CEO is available to talk about his company's recent breakthroughs with Veto Cell technology.
↧